Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
XORTX Therapeutics Inc. Common Stock
XRTX | US
2.18
USD-0.03
-1.36%
XRTX | US
Loading StockChartView...
About XORTX Therapeutics Inc. Common Stock
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
08/06/2026
Close
2.18
Open
2.17
High
2.29
Low
2.11
XORTX Therapeutics Inc. a late stage clinical pharmaceutical company engages in the development and commercialization of therapies to treat progressive kidney diseases diabetes insulin resistance metabolic syndrome diabetes diabetic nephropathy and infection. It develops XRx-008 a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101 an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and acute kidney injury (AKI) associated health consequences; and XRX-225 a program for treatment of type 2 diabetic nephropathy. The company has a collaboration and license agreements with the Icahn School of Medicine to study the incidence of AKI and hyperuricemia in patients hospitalized with COVID-19; and with the University of Florida Research Foundation Inc. XORTX Therapeutics Inc. is based in Alberta Beach Canada.
View LessXRTX | US
Risk
141.1
Sharpe
-0.57
Luna's Score
46/100
Recommendation
Hold
Luna says (XRTX | US)
What's Working
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
What's not Working
Negative Momentum (Declining Price)
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
Loading RiskMeterView...
10 days
61.5%1 month
141.1%3 months
135.5%6 months
107.6%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
0.96
Price to book
2.02
Debt to equity
0.03
Debt to assets
0.02
Ent. to EBITDA
0.09
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-3.30M
MarketCap
6.56M
MarketCap(USD)
6.56M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-29.36
Short ratio
0.07
Short perc.
1.11
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
0.64
Range1M
0.85
Range3M
3.25
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
0.49
Price X volume
40.44K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.09 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 2.02 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 135.48 | 72.80 | Riskier |
| Debt to Equity | 0.03 | -1.23 | Expensive |
| Debt to Assets | 0.02 | 0.25 | Cheaper |
| Market Cap | 6.56M | 3.66B | Emerging |
